Thomas Wood has recently joined the Clinical Trial Files podcast with Karin Avila and Taymeyah Al-Toubah, discussing the inception of the Clinical Trial Risk Tool, what impact AI can make in clinical trials, and what Alan Turing would make of it all.
This is an episode dedicated to Alan Turing’s 113th birthday on 23 June 2025.
You can find the episode on
Guest post by Youssef Soliman, medical student at Assiut University and biostatistician Before launching a clinical study, even the most promising idea must be vetted for feasibility. In other words, can this trial be executed successfully in the real world? Feasibility assessments examine practical factors like available patients, site capabilities, timelines, and budget. This step is crucial. A majority of trials encounter delays or enrollment shortfalls (by some estimates, 70–80% of trials) [1], driving up costs and risking failure.
Risk assessment is a critical process in clinical trials that involves thorough and systematic evaluation of potential risks to the study volunteers, biases affecting the results and data integrity/protection. The process requires the use of risk assessment forms to identify, evaluate, and mitigate risks and ensure patient safety and data integrity.[1] The scope of this article is to discuss whether the utilization of clinical trial assessment templates is worth the time of the study sponsors/investigators.
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan In 2025, clinical trials will continue to be a fundamental element in advancing medical science. Read more about: The Importance of Clinical Trials in Advancing Healthcare. However, as the landscape of medicine evolves, so do the ethical challenges that accompany these trials. The rapid progress of technology and the growing interconnectedness of the world present fresh ethical concerns that need to be tackled.
